



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/063,735	05/08/2002	Dan L. Eaton	P3230R1C001-168	2793
30313	7590	10/06/2004	EXAMINER	
KNOBBE, MARTENS, OLSON & BEAR, LLP			SEHARASEYON, JEGATHEESAN	
2040 MAIN STREET			ART UNIT	
IRVINE, CA 92614			PAPER NUMBER	

1647

DATE MAILED: 10/06/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/063,735

Applicant(s)

EATON ET AL.

Examiner

Jegatheesan Seharaseyon

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 September 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 11 and 12 is/are allowed.
- 6) ☒ Claim(s) 1-10 and 13-20 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 9/17/2002.
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- ☐ Notice of Informal Patent Application (PTO-152)
- ☒ Other: See Continuation Sheet.

Continuation of Attachment(s) 6). Other: Notice to comply Appendix A & B.

Art Unit: 1647

DETAILED ACTION

1. Applicant's preliminary amendment filed on 10 September 2002 is acknowledged and entered. Claims 1-20 are pending and under consideration. The claims are drawn to the nucleotide encoding protein designated PRO1774, also identified as encoded by DNA77626-1705 and ATCC accession number 203536, shown in Figures 127 (nucleic acid) and 128 (protein).

Specification

2. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

3. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825). **Applicant is required to provide a paper copy of the CRF in response to the Office Action.**

Information Disclosure Statement

4. The information disclosure statement, filed 9/17/2002, has been considered. The BLAST results demonstrate that applicants are aware of nucleic acids with identity/homology to the one claimed herein. However, as the BLAST results do not

Art Unit: 1647

give sufficient identifying information, the Examiner cannot determine if said sequences constitute prior art.

Priority Determination

5. Since no utility is disclosed in the priority applications, they aren't enabling under 35 USC 112, as required under 119(e), thus no priority is granted. Accordingly, priority under 35 U.S.C. 120 is set at the instant filing date, 5/8/02.

Should the applicant disagree with the examiner's factual determination above, it is incumbent upon the applicant to provide the serial number and specific page number(s) of any parent application filed prior to the date recited above which specifically supports the particular claim limitation for each and every claim limitation in all the pending claims which applicant considers to have been in possession of, and fully enabled for, prior to that date.

6. The utility for the instant invention is based on the sequence identity of SEQ ID NO: 128 to that of human alcohol dehydrogenase described by Meyers et al. (AAB84364, WO 01/44446, Pub. Date 06/01). The role of ADH activity in colorectal cancer is described in page: 4.

Claim Rejections - 35 USC § 112

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-6, 8-10 and 14-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

7a. The protein identified as PRO1774 (SEQ ID NO: 128) is not disclosed as being expressed on a cell surface. Accordingly, the limitation that the claimed protein comprises an "extracellular domain" (for example see claims 1, 6 and 14 parts (c) and (d)) is indefinite, as the art does not recognize soluble proteins as having such domains. Further, if the protein had an extracellular domain, the recitation of "the extracellular domain", "lacking its associated signal sequence" (claim 1, 6 and 14, part (d), for example) is indefinite as a signal sequence is not generally considered to be part of an extracellular domain, as signal sequences are cleaved from said domains in the process of secretion from the cell. Claims 2-5, 8-10 and 15-20 are rejected insofar as they are depended on rejected claims 1, 6 and 14.

7b. Claims that recite that the claimed polynucleotide "hybridizes to" another sequence, such as claim 14, are indefinite as there is no limiting definition of such in the specification, and the metes and bounds of that which will hybridize are dependent upon the conditions under which the hybridization is performed. As the metes and bounds of what will hybridize to a given sequence are entirely dependent upon the conditions of hybridization and washing, the metes and bounds of the claims cannot be determined. With respect to claim 15, although the further limitation that the hybridization conditions are "stringent" is introduced, the term "stringent conditions" is also a relative term, and

Art Unit: 1647

the metes and bounds of the claim cannot be determined. Claim 15 is rejected insofar as it is depended on rejected claim 14.

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8a. Claims 1-5 and 14-20 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabled only for the polynucleotide of SEQ ID NO: 127 or fragments of such that are usable as hybridization probes and are not enabled for polynucleotides 80, 85, 90, 95 or 99% identical to such, nor which encode a protein 80, 85, 90, 95 or 99% identical to the protein of SEQ ID NO: 128, nor polynucleotides which hybridize to any of the above because there is no structural or functional information provided in the specification. Therefore, the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is "undue" include, but are not limited to:

1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. In re *Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

Art Unit: 1647

The claims are directed to isolated polynucleotides having at least 80% identity to a SEQ ID NO: 127 or that encode the protein of SEQ ID NO: 128 with or without its signal peptide, or which encode the extracellular domain of SEQ ID NO: 128 with or without its signal peptide, or polynucleotides at least 80% identical to such encoding polynucleotides. Dependent claims are directed to polynucleotides that hybridize to the above sequences, vectors and host cells comprising the isolated polynucleotides. In the instant application, there is insufficient guidance regarding how to make PRO1774 polynucleotides variants recited in the claims.

The specification also is not enabling for the breadth of claims to polynucleotide molecules that hybridize to the disclosed sequences. It is noted that claims that recite hybridization language fail to provide adequate guidance, and do not recite that the polynucleotide encodes a protein, much less one having a specifically disclosed activity. First of all, it is pointed out that the term "hybridize" or "hybridization" generically refers to a process in which a strand of polynucleotide joins or matches up with a complementary strand through the process of base pairing, wherein the process is basically used to locate or identify DNAs encoding specific proteins. It is well established in the art that 15-20 bases have been considered sufficient to achieve this process. The breadth of the claims includes polynucleotides of as little as 10 nucleotides. With these points in mind, it is the Examiner's position that giving the claims their broadest reasonable interpretation, this language reads on an infinite number of possible DNA sequences for which there is not sufficient enablement without

Art Unit: 1647

undue experimentation because of the breath of claims, the lack of guidance provided and the quantity of experimentation needed to make or use the invention.

With respect to the hybridization use, as discussed above in paragraph 6 the invention lacks utility and thus lacks enablement. Even if utility were established, the enablement is commensurate in scope only with claims to polynucleotides that are fragments of SEQ ID NO: 127, said fragments of sufficient length to be used as hybridization probes or primers. However, enablement is *not* commensurate in scope with fragments of polynucleotides that differ from SEQ ID NO: 127 due to codon degeneracy, as it is not recognized in the art to use such sequences that are degenerate for such detection or synthesis, and the specification provides no guidance as to how or why to make such degenerate probes or primers. The specification also is not enabling for the breadth of claims to polynucleotide molecules that hybridize to the disclosed sequences because of the quantity of experimentation needed and the lack of guidance provided by the inventor.

The examples provided in the specification do not provide working examples of different DNA sequences that would enable a representative number of the above discussed DNA sequences with assurances that they can be used as probes or primers for the purpose of amplifying or detecting the PRO1774 gene. The mere recitation of this term, and the definitions provided do not serve as sufficient guidance to enable the breadth of the claims for the various DNA sequences claimed. See Ex parte Forman, 230 USPQ 546. Since the first paragraph of the statute under 35 U.S.C. 112 requires that there must be an enabling disclosure to support the breadth of the Claims, a review

Art Unit: 1647

of the specification confirms that the scope of the various DNA sequences that are discussed above have not been enabled. There is but a single polynucleotide disclosed with reference to PRO1774, SEQ ID NO: 127. In the absence of working examples, breadth of claims and sufficient guidance, it would require undue experimentation to enable a commensurate number of the sequences that are encompassed by the claims.

Since the claimed polynucleotides are described at least in part in terms of the protein that might be encoded, the scope of the protein itself must be considered. The specification asserts that PRO1774 is an unspecified secreted and transmembrane polypeptide. However, this family of proteins does not possess a common utility, but rather the proteins that can be broadly classified and have different activities, that confer different uses on them. Accordingly, the mere identification of a protein as belonging to a family, while indicative of evolutionary relatedness, is not indicative of function, nor by extension, of utility. The structure of the putative PRO1774 peptide is briefly discussed in Figure 128, as having a putative signal sequence, corresponding to amino acids 1-17. It also describes N-myristoylation sites, corresponding to about amino acids 18-24, 21-27, 22-28, 24-30, 40-46, 90-96, 109-115 and 199-205. In addition it also describes short-chain alcohol dehydrogenase sequences at amino acids 30-42 and 104-114.

The problem of predicting protein structure from sequence data and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein is extremely complex. While it is known that many amino acid substitutions are generally possible in any given protein, the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of

Art Unit: 1647

success are limited. Certain positions in the sequence are critical to the protein's structure/function relationship, e.g. such as various sites or regions directly involved in binding, activity and in providing the correct three-dimensional spatial orientation of binding and active sites. However, Applicant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue experimentation, the positions in the protein which are tolerant to change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. Therefore, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope, i.e. all the polynucleotides with the various percent identities.

8b. Claims 1-5 and 14-20 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

To provide evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof.

The claims are drawn to polynucleotides having at least 80%, 85%, 95% or 99% sequence identity with a particular disclosed sequence, or that merely hybridize to a

Art Unit: 1647

disclosed sequence. The claims do not require that the claimed polynucleotide encode a particular protein, nor that any protein encoded thereby possess any particular biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. The specification teaches that PRO1774 has (unspecified) homology to secreted and transmembrane polypeptide. The structure of the putative PRO1774 peptide is briefly discussed in Figure 128, as having a putative signal sequence, corresponding to amino acids 1-17. It also describes N-myristoylation sites, corresponding to about amino acids 18-24, 21-27, 22-28, 24-30, 40-46, 90-96, 109-115 and 199-205. In addition it also describes short-chain alcohol dehydrogenase sequences at amino acids 30-42 and 104-114. However, there is no functional characteristic associated with these motifs, hence the mere observation that they exist is not probative of function or utility. Further, there is no disclosure that the protein is expected to be a transmembrane protein, nor of any extracellular domain. In this case, the only factor present in the claim is a partial structure in the form of a recitation of percent identity. There is not even identification of any particular portion of the structure that must be conserved. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117.) The

Art Unit: 1647

specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1616.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification provided only the human sequence.

Therefore, polynucleotides comprising the sequence set forth in SEQ ID NO: 127 or encoding the protein of SEQ ID NO: 128, or fragments thereof sufficiently long to be used as hybridization probes but not the full breadth of the claims meet the written description provision of 35 U.S.C. 112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. 112 is severable from its enablement provision (see page 1115).

Claim Rejections - 35 USC § 102

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1647

A person shall be entitled to a patent unless :

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

9a. Claims 1-10 and 13-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Meyers et al. (AAB84364, WO 01/44446, Pub. Date 06/01).

Meyers et al. discloses nucleotides encoding the amino acid sequence of SEQ ID NO: 128 of the instant invention (Appendix A). In addition it discloses nucleotides that are capable of hybridizing to nucleotides encoding polypeptide of SEQ ID NO: 128 of the instant invention. Further, Meyers et al. have described the expression of nucleotides containing vectors with promoter sequences in bacterial hosts (pages 59, 83-85). With respect to the limitation of "lacking its associated signal peptide" in claims 8 and 10 as Meyers et al. teaches recombinant expression of the said polypeptide, the cDNA would produce the polypeptide identical to the present SEQ ID NO: 128, but lacking its associated signal peptide when transfected into the host cell. Thus, meeting the limitations of claims 1-10 and 13-20. Therefore, claims 1-10 and 13-20 are rejected as being anticipated by Meyers et al. (AAB84364, WO 01/44446, Pub. Date 06/01).

9b. Claims 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Birren et al. (AC003042/c, Pub. Date 07/98).

Birren et al. discloses (Appendix B) nucleotides that are capable of hybridizing to nucleotides encoding polypeptide of SEQ ID NO: 128 of the instant invention.

Art Unit: 1647

10. Claims 11 and 12 are allowable.


Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jegatheesan Seharaseyon whose telephone number is 571-272-0892. The examiner can normally be reached on M-F: 8:30-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JS 09/04


BRENDA BRUMBACK
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Notice to Comply	Application No. 10/063 ATU 735	Applicant(s) J. Eaton et al.	
	Examiner J. Seharaseyan	Art Unit 1647	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Db 181 ROELREAQTHIRATCISPGVETQFAFKLHDKDPKAAAYEQMKLPEDVAEAVIYL 240
 QY 241 STPAHIQIGDIQMRPTEQVT 260
 Db 241 STPAHIQIGDIQMRPTEQVT 260

RESULT 5
 AAU76220
 ID AAU76220 standard; protein; 260 AA.
 AC AAU76220;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE Human 21620 alcohol dehydrogenase (ADH) protein.
 XX
 KW Alcohol dehydrogenase; ADH; human; cytostatic; antiinflammatory;
 KW cerebroprotective; anti-HIV; immunomodulator; hepatotropic; metastases;
 KW pulmonary congestion; Meckel diverticulum; splenic infarction;
 KW idiopathic inflammatory bowel disease; jaundice; cholestasis;
 KW endometriosis; cerebral oedema; AIDS; leukopaenia; splenomegaly;
 KW acquired immune deficiency disease; lupus erythematosus; dermatitis;
 KW lung disease; adult respiratory distress syndrome; skin disease;
 KW bronchitis; sarcoidosis; pneumothorax; colon disorder; colitis;
 KW Crohn's disease; liver disorder; hepatitis; cirrhosis; brain disorder;
 KW meningitis; Alzheimer's disease; Huntington's disease; atherosclerosis;
 KW ischaemia; chromosome 17 (17q12-21); 21620; enzyme.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Region 166..176
 FT /note= "Short chain ADH family signature"
 XX
 PN US2002010946-A1.
 XX
 PD 24-JAN-2002.
 XX
 PF 28-FEB-2001; 2001US-00796089.
 XX
 PR 15-DEC-1999; 99US-00464039.
 PR 15-DEC-2000; 2000WO-US033873.
 XX
 PA (MILL-) MILLENNIUM PHARM INC.
 XX
 PI Meyers R;
 XX
 DR WPI; 2002-179233/23.
 DR N-PSDB; ABK15172.
 XX
 PT New human alcohol dehydrogenase (ADH) polynucleotides and polypeptides,
 PT useful as targets for diagnosing or treating ADH-related or ADH-mediated
 PT disorders, e.g. malignant breast metastases, enema or leukopenia.
 XX
 PS Claim 9; Fig 1A; 80pp; English.
 XX

This invention relates to the cDNA and protein sequences of 5 novel human
 alcohol dehydrogenase molecules. The ADH polynucleotides and polypeptides
 are useful as targets for diagnosing or treating ADH-related or ADH-
 mediated disorders, e.g. malignant breast, liver, colon or liver
 metastases, pulmonary congestion or enema, Meckel diverticulum,
 idiopathic inflammatory bowel disease, jaundice and cholestasis,
 endometriosis, cerebral oedema, AIDS, or leukopaenia. The sequences may
 also be used for treating other diseases or disorders such as spleen
 disorders (splenomegaly, splenic infarction), lung diseases (adult
 respiratory distress syndrome, bronchitis, sarcoidosis, pneumothorax),
 colon disorders (colitis, Crohn's disease), liver disorders (hepatitis,
 cirrhosis), brain disorders (meningitis, Alzheimer's disease,
 Huntington's disease), heart and blood vessel disorders (atherosclerosis,
 ischaemia), skin diseases (lupus erythematosus, dermatitis) and many
 other diseases listed in the specification. The polynucleotides and

polypeptides are also useful in screening methods to identify agonists
 and antagonists for diagnosis or treatment. In particular, the
 polypeptides and polynucleotides are useful in drug screening assays in
 cell-based assays or cell-free systems, as well as for biological assays
 related to ADHs. The ADH polypeptides are also useful for producing
 antibodies specific for the ADH regions. The polynucleotides and
 polypeptides may also be used for monitoring therapeutic effects during
 clinical trials and other treatments. The present sequence represents the
 human 21620 alcohol dehydrogenase protein of the invention the gene which
 encodes this protein has been mapped to chromosome 17 (17q12-21)

Sequence 260 AA;

Query Match 100.0%; Score 1337; DB 5; Length 260;
 Best Local Similarity 100.0%; Pred. No. 1.7e-131;
 Matches 260; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MARPGMERDRDLALVTGASGGIGAAVARALVQOGLKVVGCAARTVGNIEELAAECKSAGY 60
 DB 1 MARPGMERDRDLALVTGASGGIGAAVARALVQOGLKVVGCAARTVGNIEELAAECKSAGY 60
 QY 61 PGTLPYRCDLSNEEDILSMFSAIRSQHSGVDICINNAGLARPDTLGSGTSGWKDMFNV 120
 DB 61 PGTLPYRCDLSNEEDILSMFSAIRSQHSGVDICINNAGLARPDTLGSGTSGWKDMFNV 120
 QY 121 NVLALSICTREAYQSMKERNVDDGHHIININSMGHRVLPVSVTHFYSAKVAVTALTGL 180
 DB 121 NVLALSICTREAYQSMKERNVDDGHHIININSMGHRVLPVSVTHFYSAKVAVTALTGL 180
 QY 181 ROELREAQTHIRATCISPGVETQFAFKLHDKDPKAAAYEQMKLPEDVAEAVIYL 240
 DB 181 ROELREAQTHIRATCISPGVETQFAFKLHDKDPKAAAYEQMKLPEDVAEAVIYL 240
 QY 241 STPAHIQIGDIQMRPTEQVT 260
 DB 241 STPAHIQIGDIQMRPTEQVT 260

RESULT 6

ABUS8588
 ID ABUS8588 standard; protein; 260 AA.

XX
 AC ABUS8588;

XX
 DT 15-APR-2003 (first entry)

XX
 DE Human PRO polypeptide #189.

XX
 KW Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
 KW dog; cat; cow; horse; sheep; pig; goat; rabbit; ADEPT;
 KW antibody-dependent enzyme mediated prodrug therapy.

XX
 OS Homo sapiens.

XX
 PN US2003027272-A1.

XX
 PD 06-FEB-2003.

XX
 PF 21-JUN-2002; 2002US-00176492.

XX
 PR 18-SEP-1997; 97US-0059263P.

XX
 PR 18-SEP-1997; 97US-0059266P.

XX
 PR 17-OCT-1997; 97US-0062250P.

XX
 PR 21-OCT-1997; 97US-0063486P.

XX
 PR 24-OCT-1997; 97US-0063120P.

XX
 PR 24-OCT-1997; 97US-0063121P.

XX
 PR 28-OCT-1997; 97US-0063540P.

XX
 PR 28-OCT-1997; 97US-0063541P.

XX
 PR 28-OCT-1997; 97US-0063544P.

XX
 PR 28-OCT-1997; 97US-0063564P.

XX
 PR 31-OCT-1997; 97US-0063870P.

XX
 PR 31-OCT-1997; 97US-0064103P.

972	QY	GGATCAGCGGATACCACTTCTCTGCACACCCCGACAGGGGCTAGAAAAATTTGTTTGAG	10331
961	Db	GGATCAGCGGATACCACTTCTCTGCACACCCCGACAGGGGCTAGAAAAATTTGTTTGAG	10220
1032	QY	ATTTTATATATCATCTTGTCAAATGCTTCAGTTGTAAATGTGAAAAATGGGCTGGGGAAA	10911
1021	Db	ATTTTATATATCATCTTGTCAAATGCTTCAGTTGTAAATGTGAAAAATGGGCTGGGGAAA	10800
1092	QY	GGAGGTGGTTCCTTAATCTGTTTAATCTGTTTAACCTTGTCTTGTGCCCCCTGGGCACTTGG	11515
1081	Db	GGAGGTGGTTCCTTAATCTGTTTAATCTGTTTAACCTTGTCTTGTGCCCCCTGGGCACTTGG	11440
1152	QY	CCCTTGTCTGCTCTCAGTGTCTTCCCTTTTGACATGGGAAAAGGAGTGTGGGCCAAAATCCC	12111
1141	Db	CCCTTGTCTGCTCTCAGTGTCTTCCCTTTTGACATGGGAAAAGGAGTGTGGGCCAAAATCCC	12000
1212	QY	CATCTCTTTGCACTCAACCTGTCTGGCTCAAGGCTGGGCTGGGAGGAGGCGCTTTCAC	12711
1201	Db	CATCTCTTTGCACTCAACCTGTCTGGCTCAAGGCTGGGCTGGGAGGAGGCGCTTTCAC	12600
1272	QY	CTTATATCTGTGTGTATTATCCAGGGCTCCAGAGCTTCTCCTCTGCGCTGCCCACTGCACCC	13311
1261	Db	CTTATATCTGTGTGTATTATCCAGGGCTCCAGAGCTTCTCCTCTGCGCTGCCCACTGCACCC	13200
1332	QY	CTCTCCCCCTTATCTATCTCTCTCTGGGTTCGCCAGCCAGTCTTGGTCTTGTTCGCCCT	13911
1321	Db	CTCTCCCCCTTATCTATCTCTCTCTGGGTTCGCCAGCCAGTCTTGGTCTTGTTCGCCCT	13800
1392	QY	CCCTGGGGTCATCCCTGCCACCTCTGACTCTGACTATGCSAGCAGAACCCAGGCGCTGSCCC	14511
1381	Db	CCTGGGGTCATCCCTGCCACCTCTGACTCTGACTATGCSAGCAGAACCCAGGCGCTGSCCC	14400
1452	QY	AGTGATTTCATGTGTGATCATTTAAAAAGAAAAATCGCAACCAAAAAAATAAAAA	1505
1441	Db	AGTGATTTCATGTGTGATCATTTAAAAAGAAAAATCGCAACCAAAAAAATAAAAA	1494

```

RESULT 5
AXI179289
LOCUS AXI179289 1909 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 2 from Patent WO0144446.
ACCESSION AXI179289
VERSION AXI179289.1 GI:14598959
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
MEYERS,R.
REFERENCE 21612, 21615, 21620, 21676, 33756, novel human alcohol
AUTHORS dehydrogenases
TITLE Patent: WO 014444-A 2 21-JUN-2001;
JOURNAL Millennium Pharmaceuticals, Inc. (US)
FEATURES
Location/Qualifiers
1. 1909
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
421..1203
/note="unnamed protein product; 21620 ADH"
/codon_start=1
/protein_id="CAC43880.1"
/db_xref="GI:14598960"
/db_xref="REMTREMBL:CAC43880"
/translation="MARPEGMWRDELALVTGASGGIGAAVARALVOGLKVVGCART
VGNIEELAAASKQMGYPDCTLLPYRCDLSNEEDILSMFSAIBSOHSGVDICINNAAGLR
DPTLLSSSTSGCKMDGMYENVNVLASICTREAYOSMKERNVDDGHININNSGHRVLPFL
SVTHFYSGATKATVAATLGEGRQBELRAQTHIRATCISPGVVETQTFAPFKJHDKDPEKAA
ATYEQMKCLPEDVAEAVIYVLSTPAHIGIQMRPEQVT"
CDS
Query_Match 99.1%; Score 1492; DB 6; Length 1909;
ORIGIN

```

Best Local Similarity 99.8%; Pred. No. 4.5e-276; Matches 1503; Conservative 1; Mismatches 1; Indels 1; Gaps 1;	
QY	1 CGCGGATCGAGACCCAAAGCAGGTGCGCGCGCGCAGAGAGCGCGCGGTCACTCC 60
DB	310 CGCGGATCGAGACCCAAAGCAGGTGCGCGCGCGCAGAGAGCGCGCGGTCACTCC 369
QY	61 TCGACCCCGGTGTCGGGCTAGTCAGCAGAGCGGCGGCGGTGGCCATGCGCCAG 120
DB	370 TCGACCCCGGTGTCGGGCTAGTCAGCAGAGCGGCGGCGGTGGCCATGCGCCAG 429
QY	121 CCGGCATGAGCGGTGGCGACCGGTGCGCTGTGTGACGGGGGCTTCGGGGGGCATC 180
DB	430 CCGGCATGAGCGGTGGCGACCGGTGCGCTGTGTGACGGGGGCTTCGGGGGGCATC 489
QY	181 GGCGGCGCGTGGCCCGGCGCCTGTGTCCAGCAGGAGCTGAAGTGTGGGCTCGCGCCGC 240
DB	490 GGCGGCGCGTGGCCCGGCGCCTGTGTCCAGCAGGAGCTGAAGTGTGGGCTCGCGCCGC 549
QY	241 ACTGTGGGCAACTCGAGGAGCTGGCTCTGAATGTAAAGATGACGCTACCCCGGACT 300
DB	550 ACTGTGGGCAACTCGAGGAGCTGGCTCTGAATGTAAAGATGACGCTACCCCGGACT 609
QY	301 TTGATCCCTTACAGATGCACCTATCAAAATGAAGAGGACATCTCTCCATGTCTTCAGCT 360
DB	610 TTGATCCCTTACAGATGTGACCTATCAAAATGAAGAGGACATCTCTCTCCATGTCTTCAGCT 669
QY	361 ATCGGTTCTCAGCACAGCGGTGAGACATCTGCAATCAACAAATGTGCTTGGCCCGGCT 420
DB	670 ATCGGTTCTCAGCACAGCGGTGAGACATCTGCAATCAACAAATGTGCTTGGCCCGGCT 729
QY	421 GACACCCGTCTTCAGGACAGCACAGTGGTGGAGGACATGTTCAATGTGAACGTGCTG 480
DB	730 GACACCCGTCTTCAGGACAGCACAGTGGTGGAGGACATGTTCAATGTGAACGTGCTG 789
QY	481 GCCCTCAGCATCTGCAACGGGAAGCCTACAGTCTCATGAAGAGCGGAATGTGACGAT 540
DB	790 GCCCTCAGCATCTGCAACGGGAAGCCTACAGTCTCATGAAGAGCGGAATGTGACGAT 849
QY	541 GGGCACATCATTAACATCAATAGCATGTCTGCCACCGAGTGTATACCCCTGTCTGTGACC 600
DB	850 GGGCACATCATTAACATCAATAGCATGTCTGCCACCGAGTGTATACCCCTGTCTGTGACC 909
QY	601 CACTTCTATAGTGCACCAAGTATTCGGCTCACTGGCTGACAGAGGAGCTGAGGCAAGAG 660
DB	910 CACTTCTATAGTGCACCAAGTATTCGGCTCACTGGCTGACAGAGGAGCTGAGGCAAGAG 969
QY	661 CTTCCGGAGGCGCCAGACCCACATCCGAGCCAGTGTCTCCAGGTGTGGTGGAGACA 720
DB	970 CTTCCGGAGGCGCCAGACCCACATCCGAGCCAGTGTCTCCAGGTGTGGTGGAGACA 1029
QY	721 CAATTGCGCTTCAAACTCCAGCAAGGACCTGAGAGGAGCTGCCACTATGACAA 780
DB	1030 CAATTGCGCTTCAAACTCCAGCAAGGACCTGAGAGGAGCTGCCACTATGACAA 1089
QY	781 ATGAAGTGTCTCAAAACCCGAGGATGTGGCCGAGGCTGTATCTACGTCTTCAGCACCCCC 840
DB	1090 ATGAAGTGTCTCAAAACCCGAGGATGTGGCCGAGGCTGTATCTACGTCTTCAGCACCCCC 1149
QY	841 GCACACATCCAGATTGGAGACATCCAGATGAGGCCACCGAGCAGGTGACCTAGTGACTG 900
DB	1150 GCACACATCCAGATTGGAGACATCCAGATGAGGCCACCGAGCAGGTGACCTAGTGACTG 1209
QY	901 TGGAGGCTCTCTCCCTCCCCACCCCTTCATGGCTTGCCTCTCTCTCTGATTTTAG 960
DB	1210 TGGAGGCTCTCTCTCCCTCCCCACCCCTTCATGGCTTGCCTCTCTCTCTGATTTTAG 1269
QY	961 TGTGTATTTCTGGATCAGGGATACACTTCTGTGCCACACCCCGACAGGCGCTAGAAA 1020
DB	1270 TGTGTATTTCTGGATCAGGGATACACTTCTGTGCCACACCCCGACAGGCGCTAGAAA 1329
QY	1021 ATTTGTTTGAGATTTTATATCATCTGTGCAAAATGCTTCAGTTGTAAATGTGAAAAATG 1080

Applicant's copy

Db 1330 ATTGTTTGAATTTTATATCATCTTCTCAAAATGCTTCAGTTGTAATGTGAAAAATG 1389
Qy 1081 GCCTGGGAAAGAGGTGGTGCCTTAATGTTTACTTGTAACTTCTTCTGTCGCC 1140
Db 1390 GGTGGGAAAGAGGTGGTGCCTTAATGTTTACTTGTAACTTCTTCTGTCGCC 1449
Qy 1141 TGGGCACTTGGCTTTGTCTGCTCTCACTGCTTCCCTTTGACATGGGAAAGAGTTGTG 1200
Db 1450 TGGGCACTTGGCTTTGTCTGCTCTCACTGCTTCCCTTTGACATGGGAAAGAGTTGTG 1509
Qy 1201 GCCAAATCCCATCTTCTTGCACTCAAGCTGTGTGCTCA-GGGCTGGGTTGGCAGAG 1259
Db 1510 GCCAAATCCCATCTTCTTGCACTCAAGCTGTGTGCTYANGGCTGGGTTGGCAGAG 1569
Qy 1260 GGAGGCTTCACTTATATCTGTGTGTATCCAGGGCTCCAGACTTCTCTCTGCTG 1319
Db 1570 GGAGGCTTCACTTATATCTGTGTGTATCCAGGGCTCCAGACTTCTCTCTGCTG 1629
Qy 1320 CCCCACTGACCTCTCCCTTATCTATCTCTCTGCTTCCCTGCTCCCGAGCCAGTCTGGC 1379
Db 1630 CCCCACTGACCTCTCCCTTATCTATCTCTCTGCTTCCCTGCTCCCGAGCCAGTCTGGC 1689
Qy 1380 TTCTTGTCTCCCTCTGGGCTCATCTCCCTCACTCTGACTCTGACTATGCGAGCAACACC 1439
Db 1690 TTCTTGTCTCCCTCTGGGCTCATCTCCCTCACTCTGACTCTGACTATGCGAGCAACACC 1749
Qy 1440 AGGGCTGGCCAGTGGATTTTCATGCTGATCATTTAAAAAGAAAAATGCGAACCAAAAA 1499
Db 1750 AGGGCTGGCCAGTGGATTTTCATGCTGATCATTTAAAAAGAAAAATGCGAACCAAAAA 1809
Qy 1500 AAAAAA 1505
Db 1810 AAAAAA 1815

RESULT 6

AK026196
LOCUS AK026196 1410 bp mRNA linear PRI 13-SEP-2003
DEFINITION Homo sapiens cDNA: FLJ22543 fis, clone HSI00212.

ACCESSION AK026196

VERSION AK026196.1 GI:10438967

KEYWORDS oligo capping; fis (full insert sequence).

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

AUTHORS

1 Watanabe, K., Kumagai, A., Itakura, S., Yamazaki, M., Tashiro, H.,

Ota, T., Suzuki, Y., Obayashi, M., Nishi, T., Shibahara, T., Tanaka, T.,

Nakamura, Y., Isogai, T. and Sugano, S.

NEDO human cDNA sequencing project

Unpublished

2 (bases 1 to 1410)

Sugano, S., Suzuki, Y., Ota, T., Obayashi, M., Nishi, T., Isogai, T.,

Shibahara, T., Tanaka, T. and Nakamura, Y.

Direct Submission

Submitted (29-AUG-2000) Sumio Sugano, Institute of Medical Science,

University of Tokyo, Laboratory of Genome Structure Analysis, Human

Genome Center, Shirokane-dai, 4-6-1, Minato-ku, Tokyo 108-8639,

Japan [E-mail: fldn@nims.u-tokyo.ac.jp, Tel: 81-3-5449-5286,

Fax: 81-3-5449-5416]

NEDO human cDNA sequencing project supported by Ministry of

International Trade and Industry of Japan; cDNA full insert

sequencing; Research Association for Biotechnology; cDNA library

construction; 5'- & 3'-end one pass sequencing; Department of

Virology and Human Genome Center, Institute of Medical Science,

University of Tokyo (partly supported by Science and Technology

Agency).

FEATURES

source

Location/Qualifiers
1. 1410
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

/clone="HSI00212"
/tissue type="human small intestine"
/clone lib="HSI"
/note="cloning vector pME18SFL3"
243..788
/note="unnamed protein product"
/codon_start=1
/protein_id="BAB15390.1"
/db_xref="GI:10438968"
/translation="MSSAIRSHQSHGVDICINNAGLARPDLLSGSTSGWKDMFNVNVL
ALSICTRAYQSKERNVDDGHIININSMGHRVLPVSVTHFYSAKTVAVATLGLRL
QELRAQTHIRATCISPGVETQFAFLHDKDPEKAAATYEQMKLCKEDVAEAYIYV
LSTPAHIQIGDIQMPTPEQVT"

ORIGIN

Query Match 83.7%; Score 1259.8; DB 9; Length 1410;
Best Local Similarity 96.1%; Pred. No. 1.6e-231;
Matches 1291; Conservative 0; Mismatches 52; Indels 0; Gaps 0;
Qy 163 GGGGCTCGGGGGCATCGCGGGCGCTGGCGGGCGCTGTCAGCAGGAGCTGAAG 222
Db 57 GGGTCTAGCGGGATCGGACCAAGCAGGTGGCGGGCGCGGAGAGCGCGGGC 116
Qy 223 GTGGTGGGCTGGCGCGCACTGTGGCAACATCGAGGAGCTGGCTGCTGAATGTAAGCT 282
Db 117 GTGAGTCTCTCGACCCCGCTGTGGCAACATCGAGGAGCTGGCTGCTGAATGTAAGCT 176
Qy 283 GCAGGTACCCGGGACTTTGATCCCTACAGATGACCTATCAATGAAGAGACATC 342
Db 177 GCAGGTACCCGGGACTTTGATCCCTACAGATGACCTATCAATGAAGAGACATC 236
Qy 343 CTCTCCATGTTCTCAGCTATCGTTCTCAGCAGCAGGGGTAGACATCTGCATCAACAAT 402
Db 237 CTCTCCATGTTCTCAGCTATCGTTCTCAGCAGCAGGGGTAGACATCTGCATCAACAAT 296
Qy 403 GCTGGCTTGGCGGGCTGACACCTCTCTCAGCAGCAGCAGTGGTGGAGGACATG 462
Db 297 GCTGGCTTGGCGGGCTGACACCTCTCTCAGCAGCAGCAGTGGTGGAGGACATG 356
Qy 463 TTCAATGTGAAGTGTGGCGCTCAGCATCTGCACACGAGAGCCCTACAGTCCATGAAG 522
Db 357 TTCAATGTGAAGTGTGGCGCTCAGCATCTGCACACGAGAGCCCTACAGTCCATGAAG 416
Qy 523 GAGCGAATGTGACGATGGGACATCAATTAACATCAATAGCATGTCTGCGCCACCGAGTG 582
Db 417 GAGCGAATGTGACGATGGGACATCAATTAACATCAATAGCATGTCTGCGCCACCGAGTG 476
Qy 583 TTACCCCTGTCTGACCCACTTCTATAGTGCCACCAAGTATGCCGTGCTGCGCTGACA 642
Db 477 TTACCCCTGTCTGACCCACTTCTATAGTGCCACCAAGTATGCCGTGCTGCGCTGACA 536
Qy 643 GAGGAGTGGCAAGAGCTTGGGAGGCCAGACCCACATCCGAGCCACGTCATCTCT 702
Db 537 GAGGAGTGGCAAGAGCTTGGGAGGCCAGACCCACATCCGAGCCACGTCATCTCT 596
Qy 703 CCAGGTGTGGTGAGACAAATTCGCTTCAAACTCCACGACAGGACCCCTGAGAAGGCA 762
Db 597 CCAGGTGTGGTGAGACAAATTCGCTTCAAACTCCACGACAGGACCCCTGAGAAGGCA 656
Qy 763 GCTGCCACCTATCAGCAAAATGAGTCTCTCAAAACCGAGGAGTGGCCGAGGCTGTATC 822
Db 657 GCTGCCACCTATCAGCAAAATGAGTCTCTCAAAACCGAGGAGTGGCCGAGGCTGTATC 716
Qy 823 TAGCTCTCAGCACCCCGCCACACATCCAGATGGAGACATCCAGATGAGGCCCGGAG 882
Db 717 TAGCTCTCAGCACCCCGCCACACATCCAGATGGAGACATCCAGATGAGGCCCGGAG 776
Qy 883 CAGGTACCTATGACTGTGGGAGCTCTCTCCCTCCCACTCCCTGCTGCTGCTGCTGCT 942
Db 777 CAGGTACCTATGACTGTGGGAGCTCTCTCCCTCCCACTCCCTGCTGCTGCTGCTGCT 836
Qy 943 CTGCTCTGATTTTAGTGTGTTGATTTCTGGATCAGGATACCACTTCTGCTGCCACAC 1002

Appendix B1

Applicant's copy

Db 122 GCCTCGGGGGCATCGTGGGCGCTGGCCGGCATTAAGTCCAGAGGGACTGAAGTT 181
QY 226 GTGGCTGCGCCGCACTGTGGGCAACATCGAGGAGCTGGCTGCTGAATGTAAGAGTCA 285
Db 182 GTGGGTGTGCGCGCACCGTTGGCAACATCGAGGAGCTGGCTGCTGAATGTAAGAGTCA 241
QY 286 GGTCTACCCCGGACTTTGATCCCTACAGATGTGACCTATCAATGAAGAGGACATCTTC 345
Db 242 GGTCTACCCCGGACTTTGATCCCTACAGATGTGACCTATCAATGAAGAGGACATCTTC 301
QY 346 TCCATGTTCTAGCTATCCGTTCTCAGCACAGCGGTGTAGACATCTGCATCAACAATGCT 405
Db 302 TCCATGTTCTAGCTATCCGTTCTCAGCACAGCGGTGTAGACATCTGCATCAACAATGCT 361
QY 406 GGTCTGCGCCCGGCTGACACCTGCTCTCAGCACAGCGGTGTAGACATCTGCATCAACAATGCT 465
Db 362 GGTCTGCGCCCGGCTGACACCTGCTCTCAGCACAGCGGTGTAGACATCTGCATCAACAATGCT 421
QY 466 AATGTGAACGTGTGCGCCCTCAGCATCTGCACACCGGAGCTTACCAGTCCATGAAGGAG 525
Db 422 AATGTGAACGTGTGCGCCCTCAGCATCTGCACACCGGAGCTTACCAGTCCATGAAGGAG 481
QY 526 CGGAATGTGAGAGTGGGACATCAATTAACATCAATAGATGTCTGGCCACCGAGTGTTA 585
Db 482 CGGAATGTGAGAGTGGGACATCAATTAACATCAATAGATGTCTGGCCACCGAGTGTTC 541
QY 586 CCCCTGTCTGTGACCCACATCTTATAGTGCACCAAGTATGCCCTCACTGCGTGCACAGAG 645
Db 542 CCCAGTCTGTGATCAATCTTATAGTGCACCAAGTATGCCCTCACTGCGTGCACAGAG 601
QY 646 GACTGAGGCAAGAGTTCGGAGGCGCCAGCCACATCCGAGGACCATGTGATCTCTCA 705
Db 602 GACTGAGGCAAGAGTTCGGAGGCGCCAGCCACATCCGAGGACCATGTGATCTCTCA 661
QY 706 GGTGTGGTGGAGACAAATTCGCTTCAAACTCCACGACAGCCCTGAGAGGACGCT 765
Db 662 GGTGTGGTGGAGACAAATTCGCTTCAAACTCCACGACAGCCCTGAGAGGACGCT 721
QY 766 GGCACATATGAGCAATGAAGTGTCTCAAACTCCAGGAGTGTGGCGAGGCTGTATCTAC 825
Db 722 GGCACATATGAGCAATGAAGTGTCTCAAACTCCAGGAGGAGGCTGTATCTAC 781
QY 826 GTCCTCAGCAGCCCGCACATCCAGATGTGAGACATCCAGATGAGGCGCCACGAGGAG 885
Db 782 GTTCTTAGCACACCCCACTGTTGAGTGTGATCCAGATGAGGCGCCACGAGGAG 841
QY 886 GTGACCTAGTGTGAGGAGTCTCTCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCT 945
Db 842 GTGACCTAGTGTGAGGAGTCTCTCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCT 900
QY 946 CCTCTGGATTTAGGTGTGATTTCTGGATCAGGATCAGGATCAGGATCAGGATCAGG 1005
Db 901 CCTCTGGATTTAGGTGTGATTTCTGGATCAGGATCAGGATCAGGATCAGGATCAGG 959
QY 1006 ACCAGGGGTAGAAAATTTGTTGAGATTTTATATCATCTGTCAAAATTCCTCAGTTG 1065
Db 960 CTAAGGG-----ATAGACAGCTGTGACAGACTATCCCATTA 995
QY 1066 TAAATGTGAAAATGGCTGGGAAAGAGGTGTGCTTAAATGTTTACTTGTAAAC 1125
Db 996 CAAATGTGAAAATGGCTGGGAAAGAGGTGTGCTTAAATGTTTACTTGTAAAC 1055
QY 1126 TTGTTCTTGTGCGCCCTGAGGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1185
Db 1056 TTCTGAGTCTCTTGGGCTCGTAACTTTG-CTCTGCTGCTCTCTCTCTCTCTCTCTCT 1114
QY 1186 GGAAGAGGAGTGTGCGCAAAATCCCACTTCTTTCACCTCAACGCTGTGGCTCAGGG 1245
Db 1115 AGGAAGAGGATGATCTAGAGGGGCAATGCTCTATCTCTTACACCTACCCCCCAACC 1174
QY 1246 CT--GGGCTGGCAGGAGGAGGCTTCACTTATATCTGTGTGTTATCCAGGGCTCCAGA 1303

Db 1175 CTTAGGGTTGGAGCAGAGAGCCTCATCTTTTACCTGTGTGTGTTCCAGGGTTCAGG 1234
QY 1304 CTTCT 1363
Db 1235 TTTCT 1294
QY 1364 CC 1365
Db 1295 AC 1296

RESULT 8
AC003042/c
LOCUS 102818 bp DNA linear PRI 14-JUL-1998
DEFINITION Homo sapiens chromosome 17, clone HCIT75G16, complete sequence.
AC003042
VERSION AC003042.1 GI:3319121
KEYWORDS HTG.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 102818)
Birren, B., Fasman, K., Linton, L., Nusbaum, C. and Lander, E.
Homo sapiens chromosome 17, clone HCIT75G16
Unpublished
REFERENCE 2 (bases 1 to 102818)
Birren, B., Fasman, K., McKernan, K., Munro, C., Nusbaum, C.,
Richardson, P., Lander, E., Baldwin, J., Barna, N., Cantu, C., Chang, A.,
Cooke, P., Daly, M.J., Devon, K., Dewar, K., Dukette, B., Forrest, C.,
Gage, D., Gensheimer, S., Geraghty, K., Gilmartin, T., Hagos, B.,
Halphen, I., Harris, K., Howland, J.C., Huang, J., Hui, L., Jacotot, L.,
Kirby, A., Lane, M., Mackenzie, J., Marquis, N., McDermott, J.,
Molla, M., Morrow, J., Nachman, A., Naylor, J., O'Connor, T., Olotu, A.,
Peterson, K., Roberts, D., Rollins, G., Sarnaik, A., Shiu, P., Shyam, R.,
Stilwell, J., Stone, C., Strickland, C., Sydney, K., Tang, L.,
Zemtseva, I. and Zody, M.
Direct Submission

TITLE
JOURNAL
Submitted (31-OCT-1997) Whitehead Institute/MIT Center for Genome
Research, 320 Charles Street, Cambridge, MA 02141, USA

REFERENCE 3 (bases 1 to 102818)
Birren, B., Fasman, K., Linton, L., Nusbaum, C., Lander, E., Allen, N.,
Baker, J., Baldwin, J., Barna, N., Beckerly, R., Benn, J., Boatin, C.,
Boutwell, C., Brown, A., Castle, A., Cerny, J., Cooke, P., Depayre, E.,
Devon, K., Dewar, K., Donelan, L., Etemadi, S., Ferreira, P.,
FitzHugh, W., Forrest, C., Funke, R., Gage, D., Gardyna, S.,
Gensheimer, S., Geraghty, K., Gilmartin, T., Grant, G., Hagos, B.,
Harris, K., Horton, L., Howland, J.C., Hui, L., Jacotot, L., Kann, L.,
Macdonald, P., Marquis, N., McEwan, P., McGurk, A., McKernan, K.,
Meldrum, J., Molla, M., Morris, W., Morrow, J., Mychaleckyj, J.,
Nachman, A., Naylor, J., Naylor, J., Niloff, M., O'Connor, T., Pavlin, B.,
Peterson, K., Riley, R., Roberts, D., Rossello, R., Roy, A., Shyam, R.,
Stange-Thomann, N., Stilwell, J., Stojanovic, N., Stone, C.,
Strickland, C., Subramanian, A., Torruella-Miller, I., Vassiliev, H.,
Vo, A., Wagner, A., Wang, B., Wheeler, J., Wu, Y., Ye, W.J., Zhao, J. and
Zody, M.

TITLE
JOURNAL
Direct Submission
Submitted (14-JUL-1998) Whitehead Institute/MIT Center for Genome
Research, 320 Charles Street, Cambridge, MA 02141, USA
COMMENT On Jul 14, 1998 this sequence version replaced gi:3294535.
All repeats were identified using RepeatMasker: Smit, A.F.A. &
Green, P. (1996-1997)
http://ftp.genome.washington.edu/RM/RepeatMasker.html.

FEATURES
source
1..102818
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="17"
/map="17"
/clone="HCIT75G16"
/clone_lib="Research Genetics/Cal Tech CIB978SK-B (plates
1-194)"

